Anti-angiogenic effects and regression of localized murine AML produced by anti-VEGF and anti-Flk-1 antibodies (Q40411720)

20 September 2017

Anti-angiogenic effects and regression of localized murine AML produced by anti-VEGF and anti-Flk-1 antibodies (English)

1 reference

20 September 2017

angiogenesis inhibitor

1 reference

Fanny Reichert

1

1 reference

20 September 2017

Vivian Barak

2

1 reference

20 September 2017

Marc Tarshis

3

1 reference

20 September 2017

Gregor Prindull

4

1 reference

20 September 2017

Elizabeth Tarshis

5

1 reference

20 September 2017

Zina Ben-Ishay

6

1 reference

20 September 2017

1 July 2005

1 reference

European Journal of Haematology

20 September 2017

1 reference

20 September 2017

75

1 reference

20 September 2017

1

1 reference

20 September 2017

41-46

1 reference

Antiangiogenic cancer therapy

20 September 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00436.X

Isolation of a tumor factor responsible for angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00436.X

Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00436.X

The discovery of receptor tyrosine kinases: targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00436.X

Clinical translation of angiogenesis inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00436.X

The anti-angiogenic basis of metronomic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00436.X

Angiopoietins in tumours: the angiogenic switch

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00436.X

Akt mediates an angiogenic switch in transformed keratinocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00436.X

A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00436.X

Targeting HIF-1 for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00436.X

Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00436.X

Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00436.X

The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00436.X

Mechanisms and future directions for angiogenesis-based cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00436.X

Anti-angiogenic activity of the purine analog 6-thioguanine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00436.X

Vascular endothelial growth factor: basic science and clinical progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00436.X

Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00436.X

The protein tyrosine kinase inhibitor SU5614 inhibits VEGF-induced endothelial cell sprouting and induces growth arrest and apoptosis by inhibition of c-kit in AML cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00436.X

Protein tyrosine kinase inhibitors as novel therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00436.X

Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-kinase-dependent clonogenic response in acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00436.X

Vascular endothelial growth factor receptor Flt-1 negatively regulates developmental blood vessel formation by modulating endothelial cell division.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00436.X

High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00436.X

Novel agents for the therapy of acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00436.X

In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00436.X

10.1111/J.1600-0609.2005.00436.X

21 January 2018

Identifiers

DOI

1 reference

20 September 2017

1 reference